# Prof Paul Glue Publications

### **Chapter in Book - Research**

De Ridder, D., Manning, P., Cape, G., Vanneste, S., Langguth, B., & Glue, P. (2016). Pathophysiology-based neuromodulation for addictions: An overview. In V. R. Preedy (Ed.), Neuropathology of drug addictions and substance misuse (Vol. 1: Foundations of understanding, tobacco, alcohol, cannabinoids and opioids). (pp. 14-24). London: Elsevier. [doi: 10.1016/B978-0-12-800213-1.00002-X](http://dx.doi.org/10.1016/B978-0-12-800213-1.00002-X)

Dawson, J., Ellis, P., Glue, P., Goldsmith, D., Lenagh-Glue, J., & Smith, D. A. R. (2013). Mandatory second opinions on compulsory treatment. In J. Dawson & K. Gledhill (Eds.), New Zealand's Mental Health Act in practice. (pp. 229-246). Wellington, New Zealand: Victoria University Press.

### **Journal - Research Article**

Shadli, S. M., High, O., Byers, B., Gibbs, P., Steller, R., Glue, P., & McNaughton, N. (2019). Human anxiety-specific "theta" occurs with selective stopping and localizes to right inferior frontal gyrus. Behavioral Neuroscience. Advance online publication. [doi: 10.1037/bne0000316](http://dx.doi.org/10.1037/bne0000316)

Gale, C., Glue, P., Guaiana, G., Coverdale, J., McMurdo, M., & Wilkinson, S. (2019). Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 33(5), 543-547. [doi: 10.1177/0269881118822146](http://dx.doi.org/10.1177/0269881118822146)

Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2019). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology. Advance online publication. [doi: 10.1177/0269881119874457](http://dx.doi.org/10.1177/0269881119874457)

Thom, K., Lenagh-Glue, J., O'Brien, A. J., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2019). Service user, whānau and peer support workers' perceptions of advance directives for mental health. International Journal of Mental Health Nursing. Advance online publication. [doi: 10.1111/inm.12637](http://dx.doi.org/10.1111/inm.12637)

Le Nedelec, M., Glue, P., Winter, H., Goulton, C., Broughton, L., & Medlicott, N. (2018). Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. Drug Delivery & Translational Research, 8(3), 780-786. [doi: 10.1007/s13346-017-0476-2](http://dx.doi.org/10.1007/s13346-017-0476-2)

Le Nedelec, M., Glue, P., Winter, H., Goulton, C., & Medlicott, N. J. (2018). The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats. Journal of Psychopharmacology. Advance online publication. [doi: 10.1177/0269881118780013](http://dx.doi.org/10.1177/0269881118780013)

Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., … Loo, C. K. (2018). Repeated intranasal ketamine for treatment-resistant depression: The way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 32(4), 397-407. [doi: 10.1177/0269881118760660](http://dx.doi.org/10.1177/0269881118760660)

Menkes, D. B., Glue, P., Gale, C., Lam, F., Hung, C.-T., & Hung, N. (2018). Steady-state clozapine and norclozapine pharmacokinetics in Maori and European patients. EBioMedicine, 27, 134-137. [doi: 10.1016/j.ebiom.2017.11.030](http://dx.doi.org/10.1016/j.ebiom.2017.11.030)

Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018). Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. Journal of Psychopharmacology, 32(6), 663-667. [doi: 10.1177/0269881118762073](http://dx.doi.org/10.1177/0269881118762073)

Leitch, S., Glue, P., Gray, A. R., Greco, P., & Barak, Y. (2018). Comparison of psychosocial variables associated with loneliness in centenarian vs elderly populations in New Zealand. Jama Network Open, 1(6), e183880. [doi: 10.1001/jamanetworkopen.2018.3880](http://dx.doi.org/10.1001/jamanetworkopen.2018.3880)

Shadli, S. M., Kawe, T., Martin, D., McNaughton, N., Neehoff, S., & Glue, P. (2018). Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. International Journal of Neuropsychopharmacology, 21(8), 717-724. [doi: 10.1093/ijnp/pyy032](http://dx.doi.org/10.1093/ijnp/pyy032)

Lenagh-Glue, J., O'Brien, A., Dawson, J., Thom, K., Potiki, J., Casey, H., & Glue, P. (2018). A MAP to mental health: The process of creating a collaborative advance preferences instrument. New Zealand Medical Journal, 131(1486), 18-26. Retrieved from <https://www.nzma.org.nz/journal>

Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017). Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1302-1305. [doi: 10.1177/0269881117705089](http://dx.doi.org/10.1177/0269881117705089)

George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., … Glue, P., … Loo, C. K. (2017). Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. American Journal of Geriatric Psychiatry, 25(11), 1199-1209. [doi: 10.1016/j.jagp.2017.06.007](http://dx.doi.org/10.1016/j.jagp.2017.06.007)

Castle, C., Gray, A., Neehoff, S., & Glue, P. (2017). Effect of ketamine dose on self-rated dissociation in patients with treament refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1306-1311. [doi: 10.1177/0269881117725685](http://dx.doi.org/10.1177/0269881117725685)

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., … Harland, S., … Friedhoff, L. (2016). Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development, 5(6), 460-468. [doi: 10.1002/cpdd.254](http://dx.doi.org/10.1002/cpdd.254)

Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., … Rodgers, A. (2016). Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 19(4), 1-15. [doi: 10.1093/ijnp/pyv124](http://dx.doi.org/10.1093/ijnp/pyv124)

Shadli, S. M., Smith, M. J., Glue, P., & McNaughton, N. (2016). Testing an anxiety process biomarker: Generalisation from an auditory to a visual stimulus. Biological Psychology, 117, 50-55. [doi: 10.1016/j.biopsycho.2016.02.011](http://dx.doi.org/10.1016/j.biopsycho.2016.02.011)

Whigham, P. A., de Graaf, B., Srivastava, R., & Glue, P. (2016). Managing distance and covariate information with point-based clustering. BMC Medical Research Methodology, 16(1), 115. [doi: 10.1186/s12874-016-0218-z](http://dx.doi.org/10.1186/s12874-016-0218-z)

French, J., Glue, P., Friedman, D., Almas, M., Yardi, N., Knapp, L., … Posner, H. B. (2016). Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. Neurology, 87(12), 1242-1249. [doi: 10.1212/wnl.0000000000003118](http://dx.doi.org/10.1212/wnl.0000000000003118)

Loo, C. K., Gálvez, V., O'Keefe, E., Mitchell, P. B., Hadzi-Pavlovic, D., Leyden, J., … Glue, P. (2016). Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 134(1), 48-56. [doi: 10.1111/acps.12572](http://dx.doi.org/10.1111/acps.12572)

De Ridder, D., Vanneste, S., Gillett, G., Manning, P., Glue, P., & Langguth, B. (2016). Psychosurgery reduces uncertainty and increases free will? A review. Neuromodulation, 19, 239-248. [doi: 10.1111/ner.12405](http://dx.doi.org/10.1111/ner.12405)

Courts, J., Maskill, V., Gray, A., & Glue, P. (2016). Signs and symptoms associated with synthetic cannabinoid toxicity: Systematic review. Australasian Psychiatry, 24(6), 598-601. [doi: 10.1177/1039856216663733](http://dx.doi.org/10.1177/1039856216663733)

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Gray, A., Hung, N., … Harland, S., … Friedhoff, L. (2016). Switching opioid-dependent patients from methadone to morphine: Safety, tolerability, and methadone pharmacokinetics. Journal of Clinical Pharmacology, 56(8), 960-965. [doi: 10.1002/jcph.704](http://dx.doi.org/10.1002/jcph.704)

Glue, P., Courts, J., Gray, A., & Patterson, T. (2016). Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. New Zealand Medical Journal, 129(1433), 41-44. Retrieved from <http://www.nzma.org.nz/journal>

Forsyth, B., Machado, L., Jowett, T., Jakobi, H., Garbe, K., Winter, H., & Glue, P. (2016). Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of Ethnopharmacology, 189, 10-13. [doi: 10.1016/j.jep.2016.05.022](http://dx.doi.org/10.1016/j.jep.2016.05.022)

Glue, P., Courts, J., Gale, C., & Mason, E. (2015). Implementation of the 2013 Psychoactive Substances Act and mental health harms from synthetic cannabinoids. New Zealand Medical Journal, 128(1414). Retrieved from <https://www.nzma.org.nz/journal>

Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C.-T., & Friedhoff, L. (2015). Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 55(2), 189-194. [doi: 10.1002/jcph.404](http://dx.doi.org/10.1002/jcph.404)

Glue, P., & Herbison, P. (2015). Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis. Australian & New Zealand Journal of Psychiatry, 49(12), 1215-1220. [doi: 10.1177/0004867415614109](http://dx.doi.org/10.1177/0004867415614109)

Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh-Glue, Z., & Hung, C. T. (2015). Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(6), 680-687. [doi: 10.1002/jcph.471](http://dx.doi.org/10.1002/jcph.471)

Dawson, J., Glue, P., Ellis, P. M., Lenagh-Glue, J., Goldsmith, D., & Smith, D. A. R. (2015). Lessons from export to New Zealand of the second opinion appointed doctor scheme. BJPsych Bulletin, 39(2), 69-73. [doi: 10.1192/pb.bp.113.046540](http://dx.doi.org/10.1192/pb.bp.113.046540)

Shadli, S. M., Glue, P., McIntosh, J., & McNaughton, N. (2015). An improved human anxiety process biomarker: Characterization of frequency band, personality and pharmacology. Translational Psychiatry, 5, e699. [doi: 10.1038/tp.2015.188](http://dx.doi.org/10.1038/tp.2015.188)

Gupta, S. K., Kantesaria, B., & Glue, P. (2014). Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. Drug Discoveries & Therapeutics, 8(2), 89-95. [doi: 10.5582/ddt.8.89](http://dx.doi.org/10.5582/ddt.8.89)

Shelker, W., Poole, P., Bagg, W., Wood, I., & Glue, P. (2014). Postgraduation retention of medical students from Otago and Auckland medical programmes. New Zealand Medical Journal, 127(1388). Retrieved from <http://www.nzma.org.nz/journal>

Shelker, W., Zaharic, T., Sijnja, B., & Glue, P. (2014). Influence of rural background and rural medical training on postgraduate medical training and location in New Zealand. New Zealand Medical Journal, 127(1403). Retrieved from <http://www.nzma.org.nz/journal>

Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., … Loo, C. K. (2014). Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World Journal of Psychiatry, 15(7), 579-584. [doi: 10.3109/15622975.2014.922697](http://dx.doi.org/10.3109/15622975.2014.922697)

Baby, M., Glue, P., & Carlyle, D. (2014). 'Violence is not part of our job': A thematic analysis of psychiatric mental health nurses' experiences of patient assaults from a New Zealand perspective. Issues in Mental Health Nursing, 35(9), 647-655. [doi: 10.3109/01612840.2014.892552](http://dx.doi.org/10.3109/01612840.2014.892552)

Campbell, A., Ruffman, T., Murray, J. E., & Glue, P. (2014). Oxytocin improves emotion recognition for older males. Neurobiology of Aging, 35(10), 2246-2248. [doi: 10.1016/j.neurobiolaging.2014.04.021](http://dx.doi.org/10.1016/j.neurobiolaging.2014.04.021)

Lenagh-Glue, J., Glue, P., & Dawson, J. (2014). When the mandatory second opinion fails to approve compulsory treatment. Australasian Psychiatry, 22(4), 337-340. [doi: 10.1177/1039856214537879](http://dx.doi.org/10.1177/1039856214537879)

Dyke, J., Hendry, K., Hill, J., Schultz, M., Mason, E., & Glue, P. (2014). Management of a cluster of foreign body ingestion incidents in patients with borderline personality disorder. Open Journal of Psychiatry, 4, 99-103. [doi: 10.4236/ojpsych.2014.42014](http://dx.doi.org/10.4236/ojpsych.2014.42014)

Alvarez-Grandi, S., Leon de la Barra, S., Seifert, A., & Glue, P. (2014). Electroconvulsive therapy use in Otago, New Zealand: A 10-year retrospective audit of patient-level treatment data. Australian & New Zealand Journal of Psychiatry, 48(6), 548-553. [doi: 10.1177/0004867413514119](http://dx.doi.org/10.1177/0004867413514119)

Patterson, T., Rapsey, C. M., & Glue, P. (2013). Systematic review of cognitive development across childhood in Down syndrome: Implications for treatment interventions. Journal of Intellectual Disability Research, 57(4), 306-318. [doi: 10.1111/j.1365-2788.2012.01536.x](http://dx.doi.org/10.1111/j.1365-2788.2012.01536.x)

Gupta, S. K., Kantesaria, B., & Glue, P. (2013). Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discoveries & Therapeutics, 7(4), 158-163. [doi: 10.5582/ddt.2013.v7.4.158](http://dx.doi.org/10.5582/ddt.2013.v7.4.158)

McNaughton, N., Swart, C., Neo, P., Bates, V., & Glue, P. (2013). Anti-anxiety drugs reduce conflict-specific “theta”: A possible human anxiety-specific biomarker. Journal of Affective Disorders, 148(1), 104-111. [doi: 10.1016/j.jad.2012.11.057](http://dx.doi.org/10.1016/j.jad.2012.11.057)

Chai, Y. K., Wheeler, Z., Herbison, P., Gale, C., & Glue, P. (2013). Factors associated with hospitalization of adult psychiatric patients: Cluster analysis. Australasian Psychiatry, 21(2), 141-146. [doi: 10.1177/1039856213475682](http://dx.doi.org/10.1177/1039856213475682)

Katalinic, N., Lai, R., Somogyi, A., Mitchell, P. B., Glue, P., & Loo, C. K. (2013). Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian & New Zealand Journal of Psychiatry, 47(8), 710-727. [doi: 10.1177/0004867413486842](http://dx.doi.org/10.1177/0004867413486842)

Shelker, W., Herbison, P., Belton, A., & Glue, P. (2013). Factors related to postgraduate retention of medical graduates in New Zealand. New Zealand Medical Journal, 126(1371). Retrieved from <http://www.nzma.org.nz/journal>

Glue, P., Al-Shaqsi, S., Hancock, D., Gale, C., Strong, B., & Schep, L. (2013). Hospitalisation associated with use of the synthetic cannabinoid K2. New Zealand Medical Journal, 126(1377). Retrieved from <http://www.nzma.org.nz/journal>

Henry, M. E., Bolo, N. R., Zuo, C. S., Villafuerte, R. A., Cayetano, K., Glue, P., … Renshaw, P. F. (2013). Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrobial Agents & Chemotherapy, 57(11), 5271-5276. [doi: 10.1128/AAC.00394-13](http://dx.doi.org/10.1128/AAC.00394-13)

Grott Zanicotti, C., Perez, D., & Glue, P. (2012). Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. Journal of Palliative Medicine, 15(4), 400-403. [doi: 10.1089/jpm.2011.0314](http://dx.doi.org/10.1089/jpm.2011.0314)

Gupta, S. K., Kantesaria, B., & Glue, P. (2012). Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. European Journal of Clinical Pharmacology, 68(4), 415-418. [doi: 10.1007/s00228-011-1137-x](http://dx.doi.org/10.1007/s00228-011-1137-x)

Canton, J., Scott, K., & Glue, P. (2012). Optimal treatment of social phobia: Systematic review and meta-analysis. Neuropsychiatric Disease & Treatment, 8, 203-215. [doi: 10.2147/ndt.s23317](http://dx.doi.org/10.2147/ndt.s23317)

Glue, P., Gale, C., Menkes, D. B., & Hung, N. (2012). Evaluation of bioequivalence between clozapine suspension and tablet formulations : A multiple-dose, fed and fasted Study. Clinical Drug Investigation, 32(11), 723-727. [doi: 10.1007/s40261-012-0004-6](http://dx.doi.org/10.1007/s40261-012-0004-6)

Gandelman, K., Zhu, T., Fahmi, O. A., Glue, P., Lian, K., Obach, S., & Damle, B. (2011). Unexpected effect of rifampin on the pharmacokinetics of linezolid: In silico and in vitro approaches to explain its mechanism. Journal of Clinical Pharmacology, 51(2), 229-236. [doi: 10.1177/0091270010366445](http://dx.doi.org/10.1177/0091270010366445)

Shelker, W., Belton, A., & Glue, P. (2011). Academic performance and career choices of older medical students at the University of Otago. New Zealand Medical Journal, 124(1346). Retrieved from <http://journal.nzma.org.nz/journal/124-1346/4965/content.pdf>

Brier, M. E., Gaylor, S. K., McGovren, P., Glue, P., Fang, A., & Aronoff, G. R. (2011). Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. Journal of Clinical Pharmacology, 51(5), 731-738. [doi: 10.1177/0091270010369675](http://dx.doi.org/10.1177/0091270010369675)

Malhotra, B., Darsey, E., Crownover, P., Fang, J., & Glue, P. (2011). Comparison of pharmcokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. British Journal of Pharmacology, 72(2), 226-234. [doi: 10.1111/j.1365-2125.2011.03948.x](http://dx.doi.org/10.1111/j.1365-2125.2011.03948.x)

Tarr, G. P., Herbison, G. P., Leon de la Barra, S., & Glue, P. (2011). Study design and patient characteristics and outcome in acute mania clinical trials. Bipolar Disorders, 13(2), 125-132. [doi: 10.1111/j.1399-5618.2011.00904.x](http://dx.doi.org/10.1111/j.1399-5618.2011.00904.x)

Malhotra, B., Darsey, E., Crownover, P., Fang, J., & Glue, P. (2011). Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. British Journal of Clinical Pharmacology, 72(2), 226-234. [doi: 10.1111/j.1365-2125.2011.03948.x](http://dx.doi.org/10.1111/j.1365-2125.2011.03948.x)

Tarr, G. P., Glue, P., & Herbison, P. (2011). Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania: A systematic review and meta-analysis. Journal of Affective Disorders, 134(1-3), 14-19. [doi: 10.1016/j.jad.2010.11.009](http://dx.doi.org/10.1016/j.jad.2010.11.009)

Gandelman, K., Glue, P., Laskey, R., Jones, J., LaBadie, R., & Ose, L. (2011). An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatric Cardiology, 32(4), 433-441. [doi: 10.1007/s00246-011-9885-z](http://dx.doi.org/10.1007/s00246-011-9885-z)

Karayal, O. N., Glue, P., Bachinsky, M., Stewart, M., Chappell, P., Kolluri, S., & Cavus, I. (2011). Switching from quetiapine to ziprasidone: A sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. Journal of Psychiatric Practice, 17(2), 100-109. [doi: 10.1097/01.pra.0000396061.05269.c8](http://dx.doi.org/10.1097/01.pra.0000396061.05269.c8)

Simpson, D. M., Schifitto, G., Clifford, D. B., Murphy, T. K., Durso-De Cruz, E., Glue, P., … On behalf of the 1066 HIV Neuropathy Study Group. (2010). Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial. Neurology, 74(5), 413-420. [doi: 10.1212/WNL.0b013e3181ccc6ef](http://dx.doi.org/10.1212/WNL.0b013e3181ccc6ef)

Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010). Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Australian & New Zealand Journal of Psychiatry, 44(8), 697-705. [doi: 10.3109/00048671003705441](http://dx.doi.org/10.3109/00048671003705441)

Sweeney, K. R., Gastonguay, M. R., Benincosa, L., Cronenberger, C. L., Glue, P., & Malhotra, B. K. (2010). Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers. Drug Discoveries & Therapeutics, 4(1), 44-53.

Alemayehu, D., Andrews, E. N., Glue, P., & Knirsch, C. A. (2010). Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting. PLoS Neglected Tropical Diseases, 4(1), e564. [doi: 10.1371/journal.pntd.0000564](http://dx.doi.org/10.1371/journal.pntd.0000564)

Malhotra, B. K., Crownover, P. H., LaBadie, R., Glue, P., & MacDiarmid, S. A. (2010). The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. European Journal of Clinical Pharmacology, 66(2), 171-176. [doi: 10.1007/s00228-009-0748-y](http://dx.doi.org/10.1007/s00228-009-0748-y)

Andrews, E., Glue, P., Fang, J., Crownover, P., Tressler, R., & Damle, B. (2010). Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. British Journal of Clinical Pharmacology, 69(1), 51-57. [doi: 10.1111/j.1365-2125.2009.03546.x](http://dx.doi.org/10.1111/j.1365-2125.2009.03546.x)

Glue, P., Loan, A., & Gale, C. (2010). New prospects for the drug treatment of generalized anxiety disorder: A systematic review. Current Drug Therapy, 5(2), 86-94.

Gandelman, K., Alderman, J. A., Glue, P., Lombardo, I., LaBadie, R. R., Versavel, M., & Preskorn, S. H. (2009). The impact of calories and fat content of meals on oral ziprasidone absorption: A randomized, open-label, crossover trial. Journal of Clinical Psychiatry, 70(1), 58-62.

Lee, S., Malhotra, B., Creanga, D., Carlsson, M., & Glue, P. (2009). A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Medical Research Methodology, 9, 55. [doi: 10.1186/1471-2288-9-55](http://dx.doi.org/10.1186/1471-2288-9-55)

Damle, B. D., Uderman, H., Biswas, P., Crownover, P., Lin, C., & Glue, P. (2009). Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. British Journal of Clinical Pharmacology, 68(5), 682-689. [doi: 10.1111/j.1365-2125.2009.03499.x](http://dx.doi.org/10.1111/j.1365-2125.2009.03499.x)

Damle, B., Fosser, C., Ito, K., Tran, A., Clax, P., Uderman, H., & Glue, P. (2009). Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: A thorough QT study. Journal of Clinical Pharmacology, 49(3), 291-300. [doi: 10.1177/0091270008329551](http://dx.doi.org/10.1177/0091270008329551)

Citrome, L., Yang, R., Glue, P., & Karayal, O. N. (2009). Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophrenia Research, 111(1-3), 39-45.

Glue, P., & Patterson, T. (2009). Can drug treatments enhance learning in subjects with intellectual disability? Australian & New Zealand Journal of Psychiatry, 43(10), 899-904. [doi: 10.1080/00048670903179178](http://dx.doi.org/10.1080/00048670903179178)

El-Tahtawy, A., Glue, P., Andrews, E. N., Mardekian, J., Amsden, G. W., & Knirsch, C. A. (2008). The effect of azithromycin on ivermectin pharmacokinetics: A population pharmacokinetic model analysis. PLoS Neglected Tropical Diseases, 2(5), e236. Retrieved from [http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0000236](http://www.plosntds.org/article/info%3Adoi/10.1371/journal.pntd.0000236)

Fang, A. F., Damle, B. D., LaBadie, R. R., Crownover, P. H., Hewlett, Jr, D., & Glue, P. W. (2008). Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy, 28(1), 42-50.

Andrews, E., Damle, B. D., Fang, A., Forster, G., Crownover, P., LaBadie, R., & Glue, P. (2008). Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. British Journal of Clinical Pharmacology, 65(4), 531-539. [doi: 10.1111/j.1365-2125.2007.03084.x](http://dx.doi.org/10.1111/j.1365-2125.2007.03084.x)

Damle, B., LaBadie, R., Crownover, P., & Glue, P. (2008). Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. British Journal of Clinical Pharmacology, 65(4), 523-530. [doi: 10.1111/j.1365-2125.2007.03085.x](http://dx.doi.org/10.1111/j.1365-2125.2007.03085.x)

Malhotra, B. K., Glue, P., Sweeney, K., Anziano, R., Mancuso, J., & Wicker, P. (2007). Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clinical Pharmacology & Therapeutics, 81(3), 377-385. [doi: 10.1038/sj.clpt.6100089](http://dx.doi.org/10.1038/sj.clpt.6100089)

Miceli, J. J., Glue, P., Alderman, J., & Wilner, K. (2007). The effect of food on the absorption of oral ziprasidone. Psychopharmacology Bulletin, 40(3), 58-68.

Parker, J. D., Bart, B. A., Webb, D. J., Koren, M. J., Siegel, R. L., Wang, H., … Glue, P. (2007). Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial. Critical Care Medicine, 35(8), 1863-1868. [doi: 10.1097/01.CCM.0000269371.70738.30](http://dx.doi.org/10.1097/01.CCM.0000269371.70738.30)

Amsden, G. W., Gregory, T. B., Michalak, C. A., Glue, P., & Knirsch, C. A. (2007). Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. American Journal of Tropical Medicine & Hygiene, 76(6), 1153-1157.

Glue, P., Fang, A., Gandelman, K., & Klee, B. (2006). Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. American Journal of Therapeutics, 13(5), 418-422. [doi: 10.1097/01.mjt.0000182358.63457.48](http://dx.doi.org/10.1097/01.mjt.0000182358.63457.48)

Chung, M., Calcagni, A., Glue, P., & Bramson, C. (2006). Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. Journal of Clinical Pharmacology, 46(9), 1030-1037. [doi: 10.1177/0091270006291031](http://dx.doi.org/10.1177/0091270006291031)

### **Journal - Research Other**

Barak, Y., Leitch, S., Gale, C., & Glue, P. (2019). No seasonal influence on cognitive performance in a national sample of older adults in New Zealand [Brief report]. Australasian Journal on Ageing. Advance online publication. [doi: 10.1111/ajag.12733](http://dx.doi.org/10.1111/ajag.12733)

Johari, N., Glue, P., & Barak, Y. (2019). Screaming behaviour in response to electroconvulsive treatment: Psychogeriatric note on a patient with Alzheimer's disease. Psychogeriatrics. Advance online publication. [doi: 10.1111/psyg.12443](http://dx.doi.org/10.1111/psyg.12443)

Neehoff, S., & Glue, P. (2019). Dissociation after ketamine dosing: Is the CADSS fit for purpose? Journal of Affective Disorders, 244, 239-240. [doi: 10.1016/j.jad.2017.11.088](http://dx.doi.org/10.1016/j.jad.2017.11.088)

Ortiz, V. G., Glue, P., Somogyi, A. A., Martin, D., Alonzo, A., Rodgers, A., … Loo, C. K. (2019). A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression - the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 33(2), 260-261. [doi: 10.1177/0269881118822147](http://dx.doi.org/10.1177/0269881118822147)

Gale, C., & Glue, P. (2018). How comprehensive is suicide risk assessment in the emergency department? New Zealand Medical Journal, 131(1470), 11-13. Retrieved from <https://www.nzma.org.nz/journal>

Gale, C., Glue, P., & Barak, Y. (2018). Low-risk and high-risk groups matter in suicide risk. Psychological Medicine. Advance online publication. [doi: 10.1017/S0033291718003422](http://dx.doi.org/10.1017/S0033291718003422)

Glue, P., & Barak, Y. (2018). Prazosin for post-traumatic stress disorder. New England Journal of Medicine, 378(17), 1648-1650. [doi: 10.1056/NEJMc1803171](http://dx.doi.org/10.1056/NEJMc1803171)

Glue, P., & Menkes, D. B. (2017). Ketamine and suicidal ideation: Direct effect or epiphenomenon? Journal of Clinical Psychopharmacology, 37(2), 1. [doi: 10.1097/jcp.0000000000000646](http://dx.doi.org/10.1097/jcp.0000000000000646)

De Ridder, D., Leong, S. L., Manning, P., Vanneste, S., & Glue, P. (2017). Anterior cingulate implant for obsessive-compulsive disorder. World Neurosurgery, 97, 754.e7-754.e16. [doi: 10.1016/j.wneu.2016.10.046](http://dx.doi.org/10.1016/j.wneu.2016.10.046)

De Ridder, D., Manning, P., Glue, P., Cape, G., Langguth, B., & Vanneste, S. (2016). Anterior cingulate implant for alcohol dependence. Neurosurgery, 78(6), E883-E893. [doi: 10.1227/neu.0000000000001248](http://dx.doi.org/10.1227/neu.0000000000001248)

Henderson, S., Porter, R. J., Basset, D., Battersby, M., Baune, B. T., Byrne, G. J., Ellis, P. M., … Glue, P., … Luty, S. E., … Mulder, R., … Malhi, G. S. (2015). Why academic psychiatry is endangered. Australian & New Zealand Journal of Psychiatry, 49(1), 9-12. [doi: 10.1177/0004867414563453](http://dx.doi.org/10.1177/0004867414563453)

Mellsop, G., Ellis, P. M., Glue, P., Gale, C., Mulder, R., & Menkes, D. B. (2015). Risk management and clinical practice. New Zealand Medical Journal, 128(1424). Retrieved from <https://www.nzma.org.nz/journal>

Hendry, K., Glue, P., Hill, J., & Schultz, M. (2015). Ingestion of sharp foreign objects: A case series, literature review and management recommendation [Case review]. Journal of Gastric Disorders & Therapy, 1(1). [doi: 10.16966/jgdt.101](http://dx.doi.org/10.16966/jgdt.101)